



This is a repository copy of *Characterizing altruistic motivation in potential volunteers for SARS-CoV-2 challenge trials*.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/183451/>

Version: Submitted Version

Article:

Rose, S.M. orcid.org/0000-0003-3717-0882, Schmit, V.L. orcid.org/0000-0002-9894-0505, Darton, T.C. orcid.org/0000-0003-2209-9956 et al. (6 more authors) (Submitted: 2021)
Characterizing altruistic motivation in potential volunteers for SARS-CoV-2 challenge trials.
medRxiv. (Submitted)

<https://doi.org/10.1101/2021.03.14.21253548>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NoDerivs (CC BY-ND) licence. This licence allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the original authors. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Characterizing altruistic motivation in potential volunteers for SARS-CoV-2 challenge trials

Sophie M Rose¹, Virginia L Schmit², Thomas C Darton³, Nir Eyal^{4,5}, Monica Magalhaes⁴, Josh Morrison², Matthew Peeler⁷, Seema K Shah^{8,9} & Abigail A Marsh^{*10}

¹ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

² 1Day Sooner Research Team

³ Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom

⁴ Center for Population-Level Bioethics, Rutgers University, New Brunswick, New Jersey, USA

⁵ Department of Health Behavior, Society, and Policy, Rutgers School of Public Health, Piscataway, New Jersey, USA

⁶ Department of Philosophy, Rutgers University, New Brunswick, New Jersey, USA

⁷ Department of Mathematics, Rowan-Cabarrus Community College, Salisbury, North Carolina, USA

⁸ Smith Child Health Outcomes, Research, and Evaluation Center, Lurie Children's Hospital, Chicago, Illinois, USA

⁹ Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

¹⁰ Department of Psychology, Georgetown University, Washington, DC, USA

Abstract (150 words)

In human challenge trials, volunteers are deliberately infected with a pathogen to accelerate vaccine development and answer key scientific questions. In the U.S., preparations for challenge trials with the novel coronavirus are complete, and in the U.K., challenge trials have recently begun. However, ethical concerns have been raised about the potential for invalid consent or exploitation. These concerns largely reflect worries that challenge trial volunteers may be unusually risk-seeking or too economically vulnerable to refuse the payments these trials provide, rather than being motivated primarily by altruistic goals. We conducted the first large-scale survey of intended human challenge trial volunteers and found that SARS-CoV-2 challenge trial volunteers exhibit high levels of altruistic motivations without any special indication of poor risk perception or economic vulnerability. Findings indicate that challenge trials with the novel coronavirus can attract volunteers with background conditions, attitudes, and motivations that should allay key ethical concerns.

Keywords: human challenge trials, controlled human infection model, COVID-19, altruism, risk perception, informed consent

1 The ongoing COVID-19 pandemic presents extraordinary threats to public health and human
2 welfare. Economic and social recoveries will require ongoing development and testing of
3 prevention strategies, including vaccines that are easier to provide, store, and deliver; various
4 dosing regimens, and updating of vaccines to keep pace with emerging mutations¹. Human
5 challenge trials, in which volunteers are deliberately infected (or “challenged”) with the pathogen
6 to test vaccine candidates, are among the most efficient and scientifically powerful approaches
7 to testing vaccines and learning about early disease processes². Well-designed human
8 challenge trials can speed the development of improved vaccines by selecting the most
9 promising candidates to prioritize for further testing^{3,4,5,6,7,8}.

10 The potential for benefits from challenge trials are largely societal. By contrast, the risks and
11 burdens of challenge trials—including infection-related risks, prolonged period of
12 biocontainment and possible trial vaccine or treatment side effects—fall largely on volunteers⁹.
13 These risks and burdens (which are heightened by uncertainty about COVID-19 disease
14 outcomes) coupled with the absence of obvious direct benefits for volunteers have led some
15 bioethicists to suggest that challenge trials using the novel coronavirus may be unethical^{10,11,12}.
16 Some commentators worry that challenge trials might attract volunteers who are vulnerable to
17 undue inducement or problems understanding relevant risks, which might invalidate volunteers’
18 consent or result in their exploitation^{13,14}.

19 Addressing ethical concerns is made all the more pressing now that a COVID-19 human
20 challenge trial has recently begun in the United Kingdom¹⁵. However, there are limited data on
21 volunteer motivations and understanding for participation in human challenge trials, and none
22 on volunteers willing to participate in challenge trials with the novel coronavirus^{16,17,18}.

23 Direct benefits to participants are not required for human subjects research to be considered
24 ethical¹⁹. Instead, the totality of the benefits—including benefits to others—should be sufficient
25 to justify the risks. Trials also should be designed to expose participants to as few risks as
26 possible, and participants must be able to provide valid informed consent²⁰. This requires
27 providing volunteers with the opportunity to evaluate the risks, benefits, and alternatives to any
28 intervention to ensure that it reflects their goals, preferences, and values²¹.

29 Given the altruistic nature of challenge trial participation—with volunteers required to take on
30 personal risks and costs to achieve societal benefits—it would be ideal from an ethical
31 perspective if volunteers demonstrated highly altruistic goals, values and preferences. To date,
32 few studies have examined why healthy volunteers consent to research with net risks and

33 burdens to themselves, or whether their goals and values are compatible with ethical
34 participation^{16,17,22,23,24,25}. To assess whether a group of individuals who proactively declared
35 their intent to volunteer to participate in a COVID-19 challenge trial meets these conditions, we
36 conducted the first large-scale evaluation of characteristics of potential challenge trial
37 volunteers. Volunteers were recruited through the non-profit advocacy organization 1Day
38 Sooner (<https://www.1daysooner.org/>). 1Day Sooner was created in April 2020 to accelerate the
39 deployment of effective vaccines by supporting preparation efforts for COVID-19 challenge trials
40 and to advocate on behalf of COVID-19 human challenge trial volunteers. It curates the only
41 centralized international database of volunteers who have indicated their willingness to partake
42 in COVID-19 challenge trials.

43 We hypothesized that COVID-19 challenge trial volunteerism reflects heightened altruistic
44 values and preferences. In light of concerns that challenge trials may attract participants who
45 are unusually insensitive to risk or who are in dire economic need^{10,11,17}, we also tested the
46 alternate hypotheses that challenge trials attract participants who engage in elevated risk
47 behaviors (including specifically health and safety related risk behaviors) or those who are
48 economically or otherwise vulnerable to exploitation. Either of these issues could raise concerns
49 about the ethical permissibility of trials, although trialists could still try to select for those
50 intended volunteers who have accurate risk perceptions and no socioeconomic motivations.

51 To test these hypotheses, we conducted a pre-registered (<https://osf.io/fqyrb>) study in which we
52 measured altruistic motivation, values, and behavior; risk preferences and behaviors, and
53 sociodemographic variables in 1,911 potential COVID-19 challenge trial volunteers. We
54 compared volunteers to 999 controls recruited to reflect approximate 2019 US Census
55 demographics, whose characteristics are described in [Table 1](#).

56 **Results**

57 ***Socio-demographic variables***

58 Most volunteers (66.2%) were between 18 and 45 years of age, identified as non-Hispanic white
59 (78.5%), and had a bachelor's degree or higher (77.4%). A majority reported residing in the
60 United States (81.5%), followed by Canada (7.6%), the United Kingdom (2.3%) and Germany
61 (1.0%). Most volunteers had either private health insurance or access to healthcare through
62 publicly-funded health systems (88.1%). Approximately one in three volunteers (32.0%) lived
63 alone, and a similar proportion (34.4%) lived with only one other person. 28.7% of volunteers

64 had at least one child. Half of volunteers were employed full-time (50.8%) and most (71.9%)
65 reported an annual household income greater than US \$50,000. Of the total, 213 reported an
66 annual household income less than US \$25,000 (see [Table 1](#)); 23% of these (49/213) were
67 students.

68 Comparing the two groups, more volunteers were male (60.4%, N=1151) relative to the general
69 population and our controls (43.9%, N=439). Of volunteers, 35.3% self-identified as female
70 (N=680); 3.2% self-identified as non-binary or transgender (N=61), and 1.1% did not specify
71 their gender (N=21). Volunteers were generally younger (44.0% under age 35 versus 23.8% of
72 controls) and more educated (77.5% reported earning a Bachelor's degree or higher, versus
73 52.1% of controls). Volunteers were also wealthier; assuming equal distribution within income
74 categories, 61.9% of volunteers were above the U.S. median income (\$68,703 annually),
75 compared to 45.7% of the control group. Of volunteers, 11.8% fell below the U.S. poverty line
76 (\$26,172 annually for a family of four), compared to 23.0% of controls²⁶. Volunteers and controls
77 reported equal levels of health insurance (88.1% of both groups).

78 ***Altruistic values and preferences***


79 Following our pre-registered analysis plan, we conducted an exploratory factor analysis on
80 responses to the 10 motivations for volunteering (see Supplementary Information), which
81 returned a three factor solution, with one factor comprising the two altruistic motivations. The
82 percentages of participants who selected each of the motivations were calculated ([Table 2](#)). The
83 two altruistic motivations were the only options selected by majorities of respondents; both were
84 selected by over three-quarters of volunteers ("I wanted to help others and potentially save
85 lives" (95.9%) and "I wanted to contribute to the progress of medicine" (79.2%)). The third most
86 highly ranked choice ("I feel helpless and this is a way to do something positive" (46.6%)) was
87 selected by a minority of volunteers, as were the remaining options.

88
89 We next conducted chi-square tests to compare challenge trial volunteers' and controls' prior
90 engagement in altruistic behavior and found that volunteers were more likely than controls to
91 have participated in all but one of these behaviors ([Figure 1](#)). More volunteers reported having
92 previously donated blood (V: 75.5%, C: 62.5%, $\chi^2(1)=54.020$, $p<0.001$), having donated
93 significant amounts of money to charity (V: 75.3%, C: 50.3%, $\chi^2(1)=175.374$, $p<0.001$),
94 registering as a bone marrow donor (V: 35.5%, C: 14.7%, $\chi^2(1)=124.284$, $p<0.001$) or being a
95 registered deceased organ donor (V: 85.8%, C: 47.4%, $\chi^2(1)=460.221$, $p<0.001$). More controls

96 reported being living kidney or liver donors (V: 1.2%, C: 9.6%, $\chi^2(1)=116.813$, $p<0.001$), but
97 positive response rates for controls were implausibly high given the overall prevalence of living
98 organ donation (per capita prevalence < 1 in 100,000), suggesting results for this question may
99 not be reliable.

100

101 **Figure 1. Volunteer group motivations for participating in human challenge studies and**
102 **comparison of engagement in altruistic behaviors by volunteer vs. control groups**



103

104 We next compared volunteer and control groups along each HEXACO dimension using an
105 ANCOVA model, controlling for age, income, education level, gender and country of residence.
106 Effect sizes were calculated using eta-squared (η^2) values²⁷, with effect sizes <0.01 considered
107 trivial, effect sizes 0.01-0.06 small, effect sizes 0.06-0.14 medium, and effect sizes >0.14 large.
108 Average scores for volunteers were significantly higher than controls on all but one of the
109 HEXACO dimensions, with the largest effect sizes obtained for Honesty-Humility (V: 4.25, C:
110 3.67, $p<0.001$, $\eta^2=0.128$) and Openness to Experience (V: 3.96, C: 3.44, $p <0.001$, $\eta^2=0.119$). In
111 contrast, volunteers scored lower on Emotionality, but this effect size was small (V: 2.55, C:
112 2.84, $p=0.03$, $\eta^2 < 0.03$) ([Table 3](#)).

113 We used logistic regression analyses to predict the likelihood of a participant being in the
114 challenge study volunteer group based solely on HEXACO outcomes. Results indicated that
115 volunteer status was most strongly predicted by openness to experience (OR: 4.60, 95% CI:
116 3.91, 5.41, $d=0.841$) when controlling for the five other HEXACO dimensions. Honesty-Humility
117 was the next most strongly associated with volunteer group membership (OR: 2.36, 95% CI:
118 2.05, 2.72, $d=0.473$). Other dimensions were less strongly associated (effect sizes 0.101-
119 0.238)²⁷. This model had a Cox & Snell $R^2 = 0.246$ and an Akaike Information Criterion (AIC)
120 value of 2751.09²⁸.

121 We then added demographic covariates to the above model, including age, gender, education
122 level, income, and country of residence to control for the potential influence of these differences
123 between volunteers and controls. Results indicate that, after controlling for these variables,
124 volunteer status was most strongly associated with Openness to Experience (OR: 4.32, 95% CI:
125 3.53, 5.29, Cohen's $d=0.806$) and Honesty-Humility (OR: 4.28, 95% CI: 3.52, 5.20, Cohen's
126 $d=0.801$) ([Table 4](#) and Supplemental Table 1). Agreeableness was not associated with group
127 membership (OR: 0.99, 95% CI: 0.81, 1.21). Effect sizes for other HEXACO dimensions ranged
128 from 0.175 to 0.238. In addition, education level and income were both found to be significantly
129 associated with volunteer group membership with a large effect size ([Table 5](#)). For example,
130 study participants with an education level equivalent to a Bachelor's degree had 144-fold odds
131 of being a member of the volunteer group compared to those with less than high school
132 equivalent education (OR: 144.14, $p<0.001$, $d=2.74$). Participants with an annual income of
133 greater than \$200,000 had 4.19-fold odds of being a member of the volunteer group compared
134 to those earning less than \$25,000 annually. This model had a total Cox & Snell $R^2 = 0.432$ (with
135 HEXACO dimension covariates accounting for 16.4% of R^2) and an AIC value of 2070.92,
136 indicating that the addition of demographic covariates improved the fit of the model overall.

137 ***Risk sensitivity***

138 We next compared risk behaviors and evaluations across the two groups. We predicted that
139 volunteers would not, in general, exhibit more risk-taking behaviors or risk insensitivity relative
140 to controls²⁹. We compared groups on the six DOSPERS risk domains for each of the three
141 components using an ANCOVA model ([Table 6](#) and Supplemental Table 3 and 4), which
142 included an additional covariate for age, and included the categorical variables of income,
143 education level, gender, and US residency as fixed effects to control for the potential role of
144 demographic differences between volunteers and controls. Results indicated that volunteers
145 differed from controls in risk-taking attitudes in all domains. However, the volunteer group was
146 not consistently the more risk-seeking group. Relative to controls, volunteers demonstrated
147 greater risk-aversion in the domains of ethics, gambling, and health and safety. This effect was
148 greatest for risk aversion relating to ethical (V: 1.73, C: 2.60, $p<0.001$, $\eta^2=0.113$) and financial-
149 gambling scenarios (V: 1.40, C: 2.45, $p<0.001$, $\eta^2=0.107$). By contrast, volunteers were more
150 risk-seeking than controls with respect to financial investing, recreational activities, and social
151 behaviors (for example, challenging norms or authority). The effect size of risk-seeking was
152 greatest within the social domain (V: 5.39, C: 4.40, $p<0.001$, $\eta^2=0.126$). Other dimensions of risk-
153 taking showed small differences across the groups ($\eta^2=0.004-0.028$).

154 We also identified significant differences between volunteers and controls on the *risk-perception*
155 component of the DOSPERT across all domains, with the exception of the ethical domain. The
156 strengths of associations were mostly small or trivial ($\eta^2 < 0.01-0.06$). However, medium effects
157 were observed for the perception of social risk, which was greater in controls than volunteers (V:
158 2.71, C: 3.47, $p < 0.001$, $\eta^2 = 0.08$). Finally, with respect to the *perceived-benefits scale* of the
159 DOSPERT, volunteers perceived risk-taking behaviors in the ethical (V: 2.04, C: 2.83, $p <$
160 0.001 , $\eta^2 = 0.085$), financial-gambling (V: 2.04, C: 3.03, $p < 0.001$, $\eta^2 = 0.081$) and health and
161 safety domains (V: 1.80, C: 2.48, $p < 0.001$, $\eta^2 = 0.084$) as significantly less beneficial than did
162 controls (all medium effect sizes). Exceptions included the recreational (V: 3.27, C: 3.02, $p <$
163 0.001 , $\eta^2 = 0.006$) and social domains (V: 4.37, C: 3.94, $p < 0.001$, $\eta^2 = 0.025$), which volunteers
164 perceived as more beneficial than did controls (although differences had trivial and small effect
165 sizes, respectively).

166 Further analyses regarding risk-perception relating to COVID-19 and challenge trial participation
167 identified in the pre-registration plan were beyond the scope of this paper and will be discussed
168 in forthcoming papers.

169 **Discussion**

170 Together, these results indicate that the characteristics of volunteers for COVID-19 challenge
171 trials do not substantiate concerns regarding understanding, vulnerability, or undue influence.
172 Volunteerism was overwhelmingly associated with heightened altruistic motivation and behavior.
173 Nearly all volunteers reported altruistic motivations for volunteering, and demonstrated high
174 levels of prior engagement in other forms of altruism, including donating blood, donating money
175 to charity, and registering as living marrow donors and deceased organ donors. Volunteers also
176 scored higher in personality traits like Honesty-Humility that reflect high valuation of others
177 relative to the self³⁰. Together, these metrics suggest that those who volunteer to participate in
178 COVID-19 human challenge trials (the benefits of which primarily accrue to others) exhibit
179 reliably altruistic motivations, preferences, and values consistent with the goals of these trials.

180 We did not find evidence that challenge trial volunteerism is disproportionately associated with
181 psychological or demographic factors that might raise ethical concerns. Comparing risk
182 perceptions and behaviors between volunteers and controls, we found that group differences
183 were generally small in magnitude and did not suggest that volunteers were generally
184 insensitive to factors that compromise physical health or safety. Although volunteers indicated
185 that they would be more likely than controls to take risks in social, recreational, and investment

186 domains, they indicated being less likely to take risks in the health and safety domain. Group
187 differences in ratings may reflect in part the different risk/benefit profiles that the two groups
188 perceived for different categories of risk. Volunteers perceived slightly lower risks in the health
189 and safety domain than controls ($\eta^2=0.003$), but also perceived lower benefits to activities in that
190 domain ($\eta^2=0.087$).

191 We also found no evidence that volunteerism is associated with high levels of socioeconomic
192 vulnerability that might make volunteers subject to exploitation. Due to the lengthy quarantine
193 period required in COVID-19 challenge trials, the recently approved U.K. trial will compensate
194 volunteers £1,500 for a 17-day quarantine. We cannot rule out the possibility that this payment,
195 meant to compensate for quarantine only, may nonetheless attract people seeking economic
196 gain, which might be construed as coercion or undue inducement to participate (see Largent et
197 al 2017³¹ for a review of the debate on coercion and undue inducement). Our results indicate
198 that challenge trials will likely be able to attract participants with non-economic motives.
199 Volunteers in our sample reported higher levels of income and education relative to population
200 medians and relative to controls, and equivalent levels of health insurance as controls. The high
201 median educational attainment of volunteers (over three-quarters of whom reported having a
202 Bachelor's degree or higher) also matters, as it suggests that volunteers are relatively well-
203 positioned to understand the information disclosed during the consent process³².

204 Of note, majorities of volunteers were male and between the ages of 18 and 45. A high
205 proportion (78.5%) identified as non-Hispanic white. These socio-demographic variables confer
206 both risk factors for and protective factors against serious COVID-19 outcomes. It is generally
207 accepted that challenge trials should include only young and medically healthy volunteers^{2,33},
208 but the role that other socio-demographic risk factors should play in volunteer enrollment is
209 debated. Male biological sex confers clear risks of serious illness or death following infection,
210 with males' average case-fatality ratio being 1.7 times higher than females', an effect thought to
211 reflect sex-based differences in innate and adaptive immune responses^{34,35}. COVID-19 related
212 fatalities and hospitalizations are dramatically elevated among participants who identify as
213 Black, Latino, and Native American, likely due to structural inequities and socioeconomic factors
214 affecting health³⁶. Some advocates of COVID-19 challenge trials have proposed including
215 volunteers from diverse backgrounds to ensure adequate representation of demographic groups
216 that have been hardest hit by the pandemic³⁷. More than twenty percent of the over 38,000
217 volunteers recruited through 1Day Sooner come from underrepresented groups, suggesting that
218 challenge trials enrolling from this pool could include a diverse group of participants.

219 Together, these findings are inconsistent with expressed concerns that human challenge trials
220 with the novel coronavirus would be “*prima facie* unethical” because they would be expected to
221 follow a “pattern of exploitative recruitment”¹¹. Whereas human challenge trial recruitment could
222 be viewed as inherently exploitative if it attracted volunteers who find participation “very
223 attractive as a result of being in a socioeconomically disadvantaged position as a result of social
224 injustice”¹¹ or whose volunteerism reflects “financial desperation, or a distorted understanding of
225 the risks”³⁸, our results indicate that such trials tend to attract volunteers who are primarily
226 motivated by altruism and do not on the whole exhibit any indicators of socioeconomic or
227 psychological vulnerability to exploitation.

228 These results should be interpreted in light of certain limitations. First, the survey was
229 conducted in a sample of early volunteers who signed up with 1Day Sooner in April and May of
230 2020, the earliest weeks of its creation. Volunteers sampled here may not be representative of
231 all challenge trial volunteers, and those who have subsequently volunteered may be different.
232 We also cannot know what proportion of intended volunteers would pass exclusionary screening
233 and consent to participate in a challenge trial. It is possible that this subset would be small or
234 non-representative of the volunteers characterized in our study, similar to observations that
235 altruistic marrow donors represent only a fraction of those who initially volunteer to donate³⁹.
236 However, we have no basis for assuming what specific changes in the composition of challenge
237 trial volunteers would result in. In addition, our sample of controls, whilst recruited to reflect
238 national United States characteristics established by 2019 census data (including age, gender,
239 education and income), are not truly representative of the United States population as a whole.
240 Nor can we rule out, based on our data, the possibility that challenge trial volunteerism reflects
241 unmeasured biases related to the perception of risks and benefits, such as optimism bias^{10,40};
242 the so-called preventative or therapeutic fallacy, which reflects a common assumption that any
243 treatment offered by medical professionals must be potentially beneficial^{41,42}; or unrealistic
244 beliefs about potential personal gains. To some degree, such concerns can be resolved through
245 a robust informed consent process^{16,17,43}, which is broadly viewed as possible for COVID-19
246 challenge trials^{2,33,44,45,46}. If, as our findings suggest, intended COVID-19 challenge trial
247 volunteers are mostly aware of and prepared to take the personal risks associated with such
248 studies to benefit the greater good, then, given the large number of intended volunteers to come
249 forth in a short amount of time, we can expect that there will be a sufficient number of altruistic
250 volunteers able to provide valid consent to make these trials both ethical and feasible.

251 **Conclusions**


252 Self-interest is sometimes incorrectly assumed to be the central or sole value driving human
253 decisions^{47,48}, which may contribute to pervasive concerns that volunteerism for risky and
254 primarily other-benefiting biomedical procedures reflects undue inducement or problems
255 understanding consent. However, people vary widely in their selfish versus altruistic preferences
256 and values^{30,49}. Those who volunteer for biomedical procedures that confer net personal risks
257 and burdens without direct benefits (like kidney and marrow donations) place unusually high
258 value on others' welfare relative to their own^{39,50}. Such donations are now broadly accepted as
259 ethical despite their risks and absence of direct benefits to volunteers because they are
260 consistent with donors' values and preferences. In finding that challenge trials can attract
261 volunteers whose altruistic preferences and values align with the goals of these trials (and who
262 are not unusually vulnerable to exploitation), the present findings similarly support the possibility
263 of valid informed consent for COVID-19 challenge trials.

264 **Methods** (1225 words)

265 **Participants**

266 2,910 individuals completed a 45-minute online survey that included indices of altruistic
267 motivation, values, and behavior; an assessment of risk preferences and behaviors, and a
268 survey of sociodemographic variables. Questions presented to the volunteer and control group
269 are available in Supplementary Data. The sample included 1,911 individuals who had confirmed
270 their willingness to participate in SARS-CoV-2 challenge trials prior to May 29, 2020 and 999
271 controls. We recruited the maximum sample size possible within our financial constraints.
272 Potential challenge trial volunteers were recruited through the non-profit advocacy organization
273 1Day Sooner. Volunteers who had declared their intent to volunteer and provided their contact
274 information as well as their interest in participating in research were recruited via email ([Figure](#)
275 [2](#)).

276 **Figure 2: CONSORT Diagram of Volunteer and Control Group Enrollment and Analysis**



277
278

279 Control participants were recruited using a private research software company (Qualtrics
280 Panel), which identifies individuals through other survey-hosting platforms and is intended to be
281 reflective of the population distribution captured by the 2019 United States Census. Inclusion
282 criteria for all participants included age greater than 18 years and demonstrated proficiency in
283 English. Volunteers in the database were excluded from sampling if they were under age 18,
284 responded 'no' to a query about wanting to participate in a vaccine challenge trial, declined to
285 share their information with researchers, or declined to provide a response to a query about
286 reasons for participating (open response format). Participants who responded to this question

287 were filtered if they responded in a language other than English, or if responses were too brief
288 (≤ 5 words) to ascertain fluency in English. All participants who completed the survey were
289 compensated \$5 USD in the form of an electronic gift card. Participants who expressed interest
290 in completing the survey were allotted 7 days to complete it at a time of their choosing, and
291 could complete it in more than one sitting if they preferred. Those who did not complete the
292 survey were sent follow-up emails on Day 4 and Day 6 to give them the opportunity to complete
293 their response. The protocol was approved by the Institutional Review Board at Rutgers
294 University (Study ID: Pro2020001023) and all participants provided electronic informed consent
295 before beginning the survey. All statistical tests for this study were taken from the same sample
296 and are two-tailed tests.

297 ***Survey Instruments***

298 Indices of altruistic values and preferences were as follows: First, the volunteer group selected
299 their top three motivations for volunteering from a list of 10 possible motivations drawn from
300 consultations with a panel of challenge study researchers and bioethicists ([Table 2](#)) (controls did
301 not complete this section)^{16,18,25,51}. Two motivations were primarily altruistic in that they refer to
302 outcomes for entities outside the self (“I wanted to help others and potentially save lives” and “I
303 wanted to contribute to the progress of medicine”); the other 8 reflected various other
304 motivations (e.g., “I wanted to receive the financial reimbursement for participating” or “I was
305 curious about COVID-19”). Second, participants indicated their prior engagement in various
306 altruistic behaviors that carry varying levels of risk and cost, including blood donation,
307 registering to donate bone marrow, registering to be a deceased organ donor, donating money
308 to charity, and living organ donation. Participants completed two additional instruments
309 assessing personality traits and risk perception. The Brief HEXACO inventory is a 24-item
310 measure assessing six dimensions of personality: Honesty-Humility, Emotionality, eXtraversion,
311 Agreeableness, Conscientiousness, and Openness to Experience^{52,53}. Each item is rated on a
312 five-point scale. Unlike five-factor inventories, HEXACO inventories include a subscale
313 (Honesty-Humility) that specifically indexes attitudes and behaviors related to valuation of
314 outcomes for others versus the self (such as exploitation, manipulation, or deceit) and has been
315 consistently linked to prosocial motivation and behavior^{30,54,55}. The DOSPERT scale is a 30-item
316 index that assesses three primary components of risk attitudes (risk-taking, risk-perception and
317 perceived expected benefits) across six broad decision categories: ethical, financial (divided into
318 investment and gambling), health and safety, social, and recreational risks⁵⁶. The *risk-taking*
319 *scale* assesses respondents’ likelihood of engaging in the risky activity or behavior, the *risk-*

320 *perception scale* assesses how risky participants perceive each of these activities to be, and the
321 *expected-benefits scale* assesses how beneficial participants perceive each activity to be.
322 Responses are made using a 7-point scale (1 = Extremely unlikely/Not at all risky/No benefits at
323 all, 7 = Extremely likely/ Extremely risky/Great benefits). Finally, all participants completed an
324 assessment of socioeconomic and other demographic variables ([see Table 1](#) for a description of
325 these demographic characteristics). Regression models for all analyses included the covariates
326 of age, gender, education level, income and country of residence to control for the potential
327 influence of differences in these characteristics. Age was included as a continuous (scale)
328 variable, centered at the mean age of 43.67 years. Gender was analyzed as a categorical
329 variable, broken down into male (reference), female, self-describe or prefer not to say.
330 Education was analyzed as a categorical variable (high school equivalent or less, trade or
331 technical school, associate degree, some college, bachelor's degree, masters degree,
332 professional or doctoral degree). Income was analyzed as a categorical variable with six
333 categories: less than \$25k annual household income, \$25k-\$50k, \$50k-\$100k, \$100k-\$200k,
334 greater than \$200k, and prefer not to say. Country of residence was dichotomized as non-US
335 (reference) and US.

336 **HEXACO Analysis**

337 Analysis of the HEXACO results began with an exploratory factor analysis (EFA) to assess
338 factor components. The EFA found six factors that roughly corresponded to the six dimensions
339 captured by the HEXACO model ($r^2=0.526$) (see Supplementary Methods and Supplementary
340 Table 2 for a comparison of the HEXACO dimensions and Survey EFA components by
341 question). Therefore, subsequent analyses were performed using the standard six HEXACO
342 dimensions. Firstly, scores on each HEXACO dimension were compared across volunteer and
343 control groups using an ANCOVA model controlling for age, income, education level, country of
344 residence and gender. Subsequent analyses were conducted to determine the likelihood of
345 participants being in the volunteer or control group based on their HEXACO scores. These
346 analyses were initially conducted using a multivariate logistic regression containing only the six
347 HEXACO dimensions as independent variables, and membership in the volunteer group as the
348 dependent variable. An additional multivariate analysis including the demographic covariates of
349 age, gender, education level, income, and US residency was then conducted.

350 ***DOSPERT Analysis***

351 Preliminary analysis of the DOSPERT was also performed using EFA to match the factors of the
352 two groups to the DOSPERT domains. A separate EFA was performed on each component of
353 the DOSPERT scale (risk-taking, risk perception, and perceived expected benefits) (See
354 Supplementary Methods for a comparison of the DOSPERT factors across the three
355 components). As the association between the DOSPERT component and EFA results were
356 moderate for all three components ($r^2=0.536$, 0.568 and 0.614 respectively), further analyses
357 were performed using the original six DOSPERT domains: Ethical, Financial - Investment,
358 Financial - Gambling, Health/Safety, Recreational and Social. Risk behaviors and evaluations
359 were compared across the volunteer and control groups using an ANCOVA model that included
360 an additional covariate for age, and included the categorical variables of income, education level,
361 gender, and country of residence as fixed effects to control for the potential role of demographic
362 differences between volunteers and controls.

References

1. Johnson, C. Y. Variants mean the coronavirus is here to stay — but perhaps as a lesser threat. *Washington Post* (2021).
2. World Health Organization. Key criteria for the ethical acceptability of COVID-19 human challenge studies. (2020).
3. Meiring, J. E., Giubilini, A., Savulescu, J., Pitzer, V. E. & Pollard, A. J. Generating the Evidence for Typhoid Vaccine Introduction: Considerations for Global Disease Burden Estimates and Vaccine Testing Through Human Challenge. *Clinical Infectious Diseases* **69**, S402–S407 (2019).
4. Cooper, M. M., Loiseau, C., McCarthy, J. S. & Doolan, D. L. Human challenge models: tools to accelerate the development of malaria vaccines. *Expert Review of Vaccines* **18**, 241–251 (2019).
5. Roestenberg, M., Hoogerwerf, M.-A., Ferreira, D. M., Mordmüller, B. & Yazdanbakhsh, M. Experimental infection of human volunteers. *The Lancet Infectious Diseases* **18**, e312–e322 (2018).
6. Roestenberg, M., Kamerling, I. M. C. & de Visser, S. J. Controlled Human Infections As a Tool to Reduce Uncertainty in Clinical Vaccine Development. *Front. Med.* **5**, (2018).
7. Sauerwein, R. W., Roestenberg, M. & Moorthy, V. S. Experimental human challenge infections can accelerate clinical malaria vaccine development. *Nature Reviews Immunology* **11**, 57–64 (2011).
8. Hodgson, S. H. *et al.* What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. *The Lancet Infectious Diseases* **21**, e26–e35 (2021).
9. Nguyen, L. C. *et al.* Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development. *Clinical Infectious Diseases* **72**, 710–715 (2021).
10. Kahn, J. P., Henry, L. M., Mastroianni, A. C., Chen, W. H. & Macklin, R. Opinion: For now, it's unethical to use human challenge studies for SARS-CoV-2 vaccine development. *PNAS* **117**, 28538–28542 (2020).
11. Holm, S. Controlled human infection with SARS-CoV-2 to study COVID-19 vaccines and treatments: bioethics in Utopia. *Journal of Medical Ethics* **46**, 569–573 (2020).
12. Bramble, B. Challenge trials for a coronavirus vaccine are unethical – except for in one unlikely scenario. *The Conversation* (2020).
13. Franklin, G. M. & Grady, C. The Ethical Challenge of Infection-Inducing Challenge Experiments. *Clinical Infectious Diseases* **33**, 1028–1033 (2001).
14. Evers, D. L., Fowler, C. B., Mason, J. T. & Mimnall, R. K. Deliberate Microbial Infection Research Reveals Limitations to Current Safety Protections of Healthy Human Subjects. *Sci Eng Ethics* **21**, 1049–1064 (2015).
15. Department for Business, Energy & Industrial Strategy & The Rt Hon Kwasi Kwarteng MP. World's first coronavirus Human Challenge study receives ethics approval in the UK. GOV.UK <https://www.gov.uk/government/news/worlds-first-coronavirus-human-challenge-study-receives-ethics-approval-in-the-uk> (2021).
16. Njue, M. *et al.* Ethical considerations in Controlled Human Malaria Infection studies in low resource settings: Experiences and perceptions of study participants in a malaria Challenge study in Kenya [version 2; peer review: 2 approved]. *Wellcome Open Res* **3**, (2018).

17. Kraft, S. A. *et al.* Exploring Ethical Concerns About Human Challenge Studies: A Qualitative Study of Controlled Human Malaria Infection Study Participants' Motivations and Attitudes. *Journal of Empirical Research on Human Research Ethics* **14**, 49–60 (2019).
18. Jao, I. *et al.* Deliberately infecting healthy volunteers with malaria parasites: Perceptions and experiences of participants and other stakeholders in a Kenyan-based malaria infection study. *Bioethics* **34**, 819–832 (2020).
19. Miller, F. G. *The ethical challenges of human research: selected essays*. (Oxford University Press, 2012).
20. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. *The Belmont Report*. <https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/read-the-belmont-report/index.html> (1979).
21. Schenker, Y. & Meisel, A. Informed Consent in Clinical Care: Practical Considerations in the Effort to Achieve Ethical Goals. *JAMA* **305**, 1130–1131 (2011).
22. Evans, D. An activist's argument that participant values should guide risk–benefit ratio calculations in HIV cure research. *Journal of Medical Ethics* **43**, 100–103 (2017).
23. Sylla, L. *et al.* If We Build It, Will They Come? Perceptions of HIV Cure-Related Research by People Living with HIV in Four U.S. Cities: A Qualitative Focus Group Study. *AIDS Research and Human Retroviruses* **34**, 56–66 (2018).
24. Murray, B. R. *et al.* What risk of death would people take to be cured of HIV and why? A survey of people living with HIV. *Journal of Virus Eradication* **5**, 109–115 (2019).
25. Ogoti, B. *et al.* Factors influencing participation in controlled human infection models: a pooled analysis from six enteric fever studies [version 1; peer review: 3 approved with reservations]. *Wellcome Open Res* **4**, 153 (2019).
26. Semega, J., Kollar, M., Shrider, E. A. & Creamer, J. *Income and Poverty in the United States: 2019*. <https://www.census.gov/library/publications/2020/demo/p60-270.html> (2020).
27. Cohen, J. *Statistical power analysis for the behavioral sciences*. (L. Erlbaum Associates, 1988).
28. McElreath, R. *Statistical rethinking: a Bayesian course with examples in R and Stan*. (CRC Press, 2018).
29. Marsh, A. A. *et al.* Neural and cognitive characteristics of extraordinary altruists. *PNAS* **111**, 15036–15041 (2014).
30. Zettler, I., Thielmann, I., Hilbig, B. E. & Moshagen, M. The Nomological Net of the HEXACO Model of Personality: A Large-Scale Meta-Analytic Investigation. *Perspect Psychol Sci* **15**, 723–760 (2020).
31. Largent, E. A. & Lynch, H. F. Paying Research Participants: Regulatory Uncertainty, Conceptual Confusion, and a Path Forward. *Yale J Health Policy Law Ethics* **17**, 61–141 (2017).
32. Christopher, P. P., Foti, M. E., Roy-Bujnowski, K. & Appelbaum, P. S. Consent Form Readability and Educational Levels of Potential Participants in Mental Health Research. *PS* **58**, 227–232 (2007).
33. Eyal, N., Lipsitch, M. & Smith, P. G. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. *The Journal of Infectious Diseases* **221**, 1752–1756 (2020).

34. Scully, E. P., Haverfield, J., Ursin, R. L., Tannenbaum, C. & Klein, S. L. Considering how biological sex impacts immune responses and COVID-19 outcomes. *Nature Reviews Immunology* **20**, 442–447 (2020).
35. Peckham, H. *et al.* Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ICU admission. *Nature Communications* **11**, (2020).
36. Rossen, L. M., Branum, A. M., Ahmad, F. B., Sutton, P. & Anderson, R. N. Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020. *MMWR Morb Mortal Wkly Rep* **69**, 1522–1527 (2020).
37. McPartlin, S. O., Morrison, J., Rohrig, A. & Weijer, C. Covid-19 vaccines: Should we allow human challenge studies to infect healthy volunteers with SARS-CoV-2? *BMJ* **371**, m4258 (2020).
38. Wolemonwu, V. C. Human Challenge Trials for a COVID-19 Vaccine: Should we bother about exploitation? *VIB* **6**, (2020).
39. Vekaria, K. M. *et al.* The role of prospection in altruistic bone marrow donation decisions. *Health Psychology* **39**, 316–324 (2020).
40. Weinstein, N. D. Unrealistic optimism about future life events. *Journal of Personality and Social Psychology* **39**, 806–820 (1980).
41. Jansen, L. A. *et al.* Unrealistic Optimism in Early-Phase Oncology Trials. *IRB* **33**, 1–8 (2011).
42. Horng, S. & Grady, C. Misunderstanding in Clinical Research: Distinguishing Therapeutic Misconception, Therapeutic Misestimation, & Therapeutic Optimism. *IRB: Ethics & Human Research* **25**, 11–16 (2003).
43. Cassileth, B. R., Zupkis, R. V., Sutton-Smith, K. & March, V. Informed Consent — Why Are Its Goals Imperfectly Realized? *N Engl J Med* **302**, 896–900 (1980).
44. Jamrozik, E. & Selgelid, M. J. Ethical Issues. in *Human Challenge Studies in Endemic Settings: Ethical and Regulatory Issues* 25–82 (Springer International Publishing, 2021). doi:[10.1007/978-3-030-41480-1_3](https://doi.org/10.1007/978-3-030-41480-1_3).
45. Chappell, R. Y. & Singer, P. Pandemic ethics: the case for risky research. *Research Ethics* **16**, 1–8 (2020).
46. WHO Expert Committee on Biological Standardization. Human Challenge Trials for Vaccine Development: regulatory considerations. (2016).
47. Miller, D. T. The norm of self-interest. *American Psychologist* **54**, 1053–1060 (1999).
48. Elster, J. Chapter 3 Altruistic Behavior and Altruistic Motivations. in *Handbook of the Economics of Giving, Altruism and Reciprocity* (eds. Kolm, S.-C. & Ythier, J. M.) vol. 1 183–206 (Elsevier, 2006).
49. Schwartz, S. H. Universals in the Content and Structure of Values: Theoretical Advances and Empirical Tests in 20 Countries. in *Advances in Experimental Social Psychology* (ed. Zanna, M. P.) vol. 25 1–65 (Academic Press, 1992).
50. Vekaria, K. M., Brethel-Haurwitz, K. M., Cardinale, E. M., Stoycos, S. A. & Marsh, A. A. Social discounting and distance perceptions in costly altruism. *Nature Human Behaviour* **1**, 1–7 (2017).
51. Hoogerwerf, M.-A., Vries, M. de & Roestenberg, M. Money-oriented risk-takers or deliberate decision-makers: a cross-sectional survey study of participants in controlled human infection trials. *BMJ Open* **10**, e033796 (2020).

52. de Vries, R. E. The 24-item Brief HEXACO Inventory (BHI). *Journal of Research in Personality* **47**, 871–880 (2013).
53. Lee, K. & Ashton, M. C. Psychometric Properties of the HEXACO Personality Inventory. *Multivariate Behavioral Research* **39**, 329–358 (2004).
54. Brocklebank, S., Pauls, S., Rockmore, D. & Bates, T. C. A spectral clustering approach to the structure of personality: Contrasting the FFM and HEXACO models. *Journal of Research in Personality* **57**, 100–109 (2015).
55. Weller, J. A. & Tikir, A. Predicting domain-specific risk taking with the HEXACO personality structure. *Journal of Behavioral Decision Making* **24**, 180–201 (2011).
56. Blais, A.-R. & Weber, E. U. A Domain-Specific Risk-Taking (DOSPERT) Scale for Adult Populations. *Judgment and Decision Making* **1**, 33–47 (2006).

Figure Captions

Figure 1. (A) Participants in the volunteer group were asked to indicate their top three motivations for participating in a COVID-19 challenge trial from a list of ten options. Selections were not ranked, and total percentages add to 300% because each participant selected 3 options. The two most commonly selected options were “I wanted to help others and potentially save lives” (95.9%) and “I wanted to contribute to the progress of medicine” (79.2%). **(B)** Participants in volunteer and control groups were surveyed on their engagement with a range of altruistic behaviors, including blood donation, significant charitable donations and organ/marrow donor status. Volunteers were significantly more likely than controls to have participated in all but one of the altruistic behaviors.

Figure 2. Overall, 9,976 volunteers from the 1Day Sooner database who had indicated they were interested in contributing to further research were contacted to participate in our study. Of these, 7,486 volunteers did not reply or declined to participate. The remaining 2,490 volunteers completed the survey via the Qualtrics platform. 579 of these responses were ultimately excluded from the final analysis, due to failure to complete sufficient portions of the survey, missing data or submitting a birth date that indicated they were under 18 years of age. The remaining 1,911 responses were then analyzed.

Tables

Table 1: Participant demographic characteristics

	Volunteer Group (n=1911) N.o. people (%)	Control (n=999) N.o. people (%)
Age		
18-25	252 (13.3)	91 (9.4)
26-35	580 (30.7)	139 (14.4)
36-45	419 (22.2)	195 (20.1)
46-55	297 (15.7)	189 (19.5)
56-65	229 (12.1)	139 (14.4)
66-75	99 (5.2)	180 (18.6)
76+	12 (0.6)	35 (3.5)
Non-responses	23	31
Gender		
Male	1151 (60.4)	436 (43.9)
Female	673 (35.3)	522 (52.5)
Self-identify/Prefer not to say	82 (4.3)	36 (3.6)
Non-response	5	5
Marital Status		
Single (never married)	976 (51.1)	289 (29.1)
Married/Domestic partnership	664 (34.7)	523 (52.6)
Divorced	200 (10.5)	121 (12.2)
Widowed	27 (1.4)	48 (4.8)
Separated	44 (2.3)	13 (1.3)
Non-responses	0	5
Race/Ethnicity		
Selected African (Yes/No (%Yes))	28/1883 (1.5)	95/904 (9.5)
Selected Hispanic (Yes/No (%Yes))	133/1778 (7.0)	59/940 (5.9)
Selected Caucasian (Yes/No (%Yes))	1595/316 (83.5)	706/293 (70.7)

Altruistic motivation in COVID-19 challenge trial volunteers 7

Selected Asian (Yes/No (% Yes))	162/1749 (8.5)	110/889 (12.4)
Selected Native American (Yes/No (% Yes))	32/1879 (1.7)	19/980 (1.9)
Employment (Top 5 categories listed)		
Employed	1009 (52.8)	394 (39.4)
Self-employed/Freelance	197 (10.3)	52 (5.2)
Retired	137 (7.2)	240 (24.0)
Studying	121 (6.3)	36 (3.6)
Unemployed/Looking for work	115 (6.0)	80 (8.0)
Employment Status		
Employed full-time	941 (49.3)	323 (32.6)
Unemployed	728 (38.2)	593 (59.9)
Employed part-time	239 (12.5)	74 (7.5)
Non-responses	3	9
Income (in USD)		
Less than \$25K	211 (11.0)	217 (21.8)
\$25K-\$50K	326 (17.1)	248 (24.9)
\$50K-\$100K	512 (26.8)	203 (20.4)
\$100K-\$200K	458 (24.0)	240 (24.1)
Greater than \$200K	260 (13.6)	67 (6.7)
Prefer not to say	143 (7.5)	21 (2.1)
Non-responses	1	3
Have health insurance		
Yes	1683 (88.1)	877 (88.1)
No	180 (9.4)	95 (9.5)
Not sure	29 (1.5)	10 (1.0)
Prefer not to say	18 (0.9)	14 (1.4)
Non-responses	1	3
Have Children (Yes/No (% Yes))	549/1360 (28.8)	494/499 (49.7)
Non-responses	2	6

Altruistic motivation in COVID-19 challenge trial volunteers 8

Number in Household (other than self)		
0	611 (32.2)	267 (27.0)
1	656 (34.5)	353 (35.7)
2	260 (13.7)	152 (15.4)
3	228 (12.0)	116 (11.7)
4	89 (4.7)	73 (7.4)
5	34 (1.8)	21 (2.1)
6	11 (0.6)	5 (0.5)
7	2 (0.1)	2 (0.2)
8+	9 (0.5)	1 (0.1)
Non-responses	11	9
Education Level		
Less than High School	4 (0.2)	22 (2.2)
High School Graduate/GED	84 (4.4)	163 (16.3)
Some college, no degree	218 (11.4)	149 (14.9)
Trade/Technical training	65 (3.4)	42 (4.2)
Associate degree	59 (3.1)	102 (10.2)
Bachelor's degree	684 (35.8)	280 (28.1)
Master's degree	498 (26.1)	172 (17.3)
Professional degree	119 (6.2)	44 (4.4)
Doctoral degree	180 (9.4)	23 (2.3)
Non-responses	0	2

Table 2: Volunteer group motivations for participating in human challenge studies

Motivation	Number (%) rating motivation in the top three reasons for volunteering ¹
I wanted to help others and potentially save lives	1832 (95.9)
I wanted to contribute to the progress of medicine	1513 (79.2)
I feel helpless and this is a way to do something positive	890 (46.6)
Another factor not mentioned	380 (19.9)
I wanted to be part of a clinical trial	348 (18.2)
I am likely to be infected by COVID-19 anyway	282 (14.8)
I was curious about COVID-19	170 (8.9)
I wanted to be guaranteed access to critical care should I be infected with COVID-19	156 (8.2)
I wanted to find out more about my own health	83 (4.3)
I wanted to receive the financial reimbursement for participating	79 (4.1)

¹ Since volunteers were asked to rate whether the choices above were in their top three reasons, percentages total 300% instead of 100% (with exceptions due to rounding).

Table 3: Comparisons of HEXACO dimension scores by volunteer vs. control group membership

	Volunteer Group (n=1911)		Control (n=999)		p-value	η ²
	Mean (SE)	95% CI	Mean (SE)	95% CI		
Honesty-Humility (H)	4.249 (0.015)	4.219, 4.278	3.672 (0.022)	3.629, 3.715	<0.001	0.128
Emotionality (E)	2.554 (0.016)	2.523, 2.585	2.840 (0.023)	2.795, 2.885	<0.001	0.032
EXtraversion (X)	3.915 (0.016)	3.883, 3.947	3.483 (0.024)	3.436, 3.530	<0.001	0.065
Agreeableness (A)	3.071 (0.014)	3.044, 3.099	2.918 (0.021)	2.878, 2.958	<0.001	0.012
Conscientiousness (C)	3.727 (0.016)	3.697, 3.758	3.498 (0.023)	3.453, 3.543	<0.001	0.021
Openness to	3.964 (0.014)	3.936, 3.991	3.442 (0.021)	3.402, 3.483	<0.001	0.119

Altruistic motivation in COVID-19 challenge trial volunteers 10

Experience (O)					
<p>Age was considered a covariate and the other categorical variables were treated as fixed effects. Marginal means by group are the means for the two groups controlled for all covariates (assuming the mean age of the sample of 43.58). P-values were calculated using F-tests. Effect sizes were calculated using eta-squared (η^2), with cutpoints for small, medium, and large effects defined as 0.01, 0.06, and 0.14 respectively.</p>					

Table 4: Odds of challenge volunteer membership by HEXACO dimension using logistic regression model, adjusted for gender, age, education, country of residence and income

HEXACO Dimension	Wald statistic	p-value	Odds Ratio	95% CI for OR	Cohen's d
Honesty/Humility	214.268	< 0.001	4.278	3.521, 5.197	0.801
Emotionality	15.675	< 0.001	0.684	0.567, 0.826	0.209
eXtraversion	22.814	< 0.001	1.539	1.289, 1.836	0.238
Agreeableness	0.012	0.912	0.989	0.811, 1.206	
Conscientiousness	10.309	0.001	0.728	0.600, 0.884	0.175
Openness to Experience	199.581	< 0.001	4.318	3.525, 5.290	0.806

Table 5: Odds of challenge volunteer membership by gender, age, education, country of residence and income using logistic regression model, adjusted for HEXACO dimensions

Covariate	Category	Wald	p-value	Odds Ratio	Cohen's d
Age	>43.67 years	229.729	< 0.001	0.938	0.035
Country of Residence	US Resident	84.017	< 0.001	0.032	1.898
Gender	Female	56.887	< 0.001	0.400	0.505
	Self-Describe	4.032	0.045	2.234	0.443
	Prefer not to say	1.633	0.201	0.542	0.338
Education	High School	9.224	0.002	26.554	1.808
	Associate	12.235	< 0.001	45.843	2.109
	Some college	18.239	< 0.001	101.516	2.547

Altruistic motivation in COVID-19 challenge trial volunteers 11

	Bachelor's	21.306	< 0.001	144.142	2.741
	Masters	23.931	< 0.001	197.931	2.915
	Doctoral	31.619	< 0.001	526.136	3.454
	Professional	20.433	< 0.001	142.864	2.736
	Trade/Technical	15.812	< 0.001	82.654	2.434
Income	\$25k-\$50k	9.679	0.002	1.880	0.348
	\$50k-\$100k	28.734	< 0.001	2.873	0.582
	\$100k-\$200k	12.297	< 0.001	1.996	0.381
	\$200k +	33.161	< 0.001	4.195	0.791
	Prefer not to say	62.390	< 0.001	17.841	1.589

Table 6: Comparisons of DOSPERT risk attitude component scores

	Volunteer Group (n=1911)		Control (n=999)		p-value	η ²
	Mean (SE)	95% CI	Mean (SE)	95% CI		
Risk taking likelihood						
Ethical	1.730 (0.025)	1.682, 1.778	2.598 (0.036)	2.528, 2.668	<0.001	0.113
Financial - Investment	3.700 (0.034)	3.635, 3.766	3.496 (0.049)	3.400, 3.591	0.001	0.004
Financial - Gambling	1.398 (0.031)	1.338, 1.458	2.448 (0.045)	2.361, 2.536	<0.001	0.107
Health/Safety	2.590 (0.028)	2.535, 2.644	2.913 (0.041)	2.833, 2.993	<0.001	0.013
Recreational	3.543 (0.035)	3.473, 3.612	2.953 (0.051)	2.852, 3.054	<0.001	0.028
Social	5.394 (0.025)	5.346, 5.443	4.467 (0.036)	4.397, 4.538	<0.001	0.126
Risk perception						
Ethical	4.712 (0.030)	4.652, 4.771	4.697 (0.044)	4.610, 4.783	0.791	-
Financial - Investment	4.299 (0.030)	4.240, 4.358	4.597 (0.044)	4.511, 4.683	<0.001	0.010

Altruistic motivation in COVID-19 challenge trial volunteers 12

Financial - Gambling	5.569 (0.039)	5.493, 5.645	5.226 (0.056)	5.115, 5.336	<0.001	0.008
Health/Safety	4.836 (0.027)	4.783, 4.890	4.971 (0.040)	4.893, 5.050	0.009	0.002
Recreational	4.074 (0.028)	4.018, 4.130	4.694 (0.041)	4.613, 4.775	<0.001	0.046
Social	2.710 (0.026)	2.660, 2.760	3.468 (0.037)	3.395, 3.541	<0.001	0.082
Perceived benefits	Mean (SE)	95% CI	Mean (SE)	95% CI	p-value	η²
Ethical	2.041 (0.026)	1.990, 2.093	2.831 (0.038)	2.757, 2.906	<0.001	0.085
Financial - Investment	3.729 (0.032)	3.665, 3.793	3.638 (0.047)	3.545, 3.730	0.135	-
Financial - Gambling	2.035 (0.034)	1.969, 2.101	3.027 (0.049)	2.931, 3.123	<0.001	0.081
Health/Safety	1.796 (0.025)	1.719, 1.819	2.529 (0.037)	2.457, 2.601	<0.001	0.084
Recreational	3.267 (0.034)	3.201, 3.333	3.015 (0.049)	2.919, 3.111	<0.001	0.006
Social	4.370 (0.027)	4.317, 4.423	3.937 (0.039)	3.860, 4.014	<0.001	0.025
<p><i>Comparison F-tests were performed for the volunteer and control groups on all three separate scale scores for the DOSPERT risk assessment test, controlled for age, income, country of residence, education level and gender (using an ANCOVA model with Age as a covariate and the other categorical variables as fixed effects).</i></p>						